Drug:
Reaction: DERMATITIS ATOPIC
20250101 - 20251231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 25134207 |
US |
2 | |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 102 | 25134208 |
US |
57 | 2 |
Visual impairment, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 103 | 25134376 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 104 | 25134435 |
US |
21 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 105 | 25134727 |
US |
2 | |
Pain, Impaired quality of life, Dermatitis atopic, Rash, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, PREDNISONE, |
||||
| 106 | 25134728 |
US |
1 | |
Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 107 | 25134889 |
US |
20 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 108 | 25134890 |
US |
4 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 109 | 25134896 |
US |
81 | 2 |
Dermatitis atopic, Rash macular, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 110 | 25134957 |
US |
23 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 111 | 25134959 |
US |
53 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 112 | 25134986 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 113 | 25135218 |
US |
19 | 2 |
Pruritus, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 114 | 25135336 |
US |
49 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 115 | 25135355 |
US |
1 | |
Dermatitis atopic, Product dose omission issue, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 116 | 25135380 |
US |
26 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 117 | 25135403 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 118 | 25135438 |
US |
34 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 119 | 25135457 |
US |
66 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 120 | 25135492 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 121 | 25135765 |
US |
1 | |
Pruritus, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 122 | 25136024 |
US |
74 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 123 | 25136217 |
US |
33 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 124 | 25136273 |
US |
33 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 125 | 25136330 |
US |
74 | 1 |
Dermatitis atopic, Eczema, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 126 | 25136786 |
US |
19 | 2 |
Meniscus injury, Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 127 | 25137074 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 128 | 25137082 |
US |
60 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 129 | 25137107 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 130 | 25126270 |
US |
50 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 131 | 25126273 |
US |
27 | 2 |
Dermatitis atopic, Rash, Pruritus, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 132 | 25126314 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 133 | 25126327 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 134 | 25126765 |
US |
48 | 2 |
Drug ineffective, Rash pruritic, Plastic surgery, Dermatitis atopic, Pigmentation disorder, Benign neoplasm of skin, |
||||
PREDNISONE, PREDNISONE, PREDNISONE, PREDNISONE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, |
||||
| 135 | 25127657 |
US |
54 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 136 | 25127668 |
US |
41 | 1 |
Pruritus, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 137 | 25127687 |
US |
16 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 138 | 25128369 |
US |
41 | 2 |
Illness, Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 139 | 25128377 |
US |
17 | 1 |
Dermatitis atopic, Dermatitis, |
||||
TRALOKINUMAB-LDRM, |
||||
| 140 | 25128392 |
US |
40 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, |
||||
| 141 | 25128636 |
US |
2 | |
Cutaneous T-cell lymphoma, Dermatitis atopic, Urticaria, |
||||
TRALOKINUMAB-LDRM, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 142 | 25128690 |
US |
37 | 1 |
Dermatitis atopic, Rash pruritic, Scratch, |
||||
DUPILUMAB, |
||||
| 143 | 25128701 |
US |
75 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 144 | 25128709 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 145 | 25128710 |
US |
1 | 1 |
Dry skin, Sleep disorder, Pruritus, Therapeutic response decreased, Dry eye, Eye irritation, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 146 | 25128713 |
US |
1 | |
Vitiligo, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 147 | 25128764 |
US |
54 | 1 |
Rash erythematous, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 148 | 25128787 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 149 | 25128792 |
US |
3 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 150 | 25128799 |
US |
70 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 151 | 25128800 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 152 | 25128803 |
US |
38 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 153 | 25128808 |
US |
54 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 154 | 25128816 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 155 | 25128819 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 156 | 25128825 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 157 | 25128826 |
US |
53 | 1 |
Dermatitis atopic, Pigmentation disorder, |
||||
DUPILUMAB, |
||||
| 158 | 25128827 |
US |
35 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 159 | 25128828 |
US |
56 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 160 | 25128837 |
US |
22 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 161 | 25128840 |
US |
52 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 162 | 25128849 |
US |
51 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 163 | 25128863 |
US |
7 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 164 | 25128865 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 165 | 25128872 |
US |
43 | 2 |
Stress, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 166 | 25128874 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 167 | 25128910 |
US |
55 | 2 |
Dermatitis atopic, Condition aggravated, Rash macular, |
||||
DUPILUMAB, |
||||
| 168 | 25128974 |
US |
81 | 2 |
Allergy to chemicals, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 169 | 25128980 |
US |
53 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 170 | 25128983 |
US |
44 | 1 |
Dermatitis atopic, Pruritus, Dry skin, Skin exfoliation, Injection site pain, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 171 | 25128995 |
US |
21 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 172 | 25129004 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 173 | 25129043 |
US |
21 | 2 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 174 | 25129173 |
US |
5 | 2 |
Dermatitis atopic, Rash, Pruritus, |
||||
DUPILUMAB, |
||||
| 175 | 25129257 |
US |
49 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 176 | 25129519 |
US |
36 | 1 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 177 | 25129579 |
US |
35 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 178 | 25129580 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 179 | 25129906 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 180 | 25129991 |
US |
60 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 181 | 25130110 |
US |
45 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 182 | 25130112 |
US |
39 | 2 |
Stress, Irritability, Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 183 | 25130458 |
US |
37 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 184 | 25130502 |
US |
28 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 185 | 25130603 |
US |
2 | |
Dermatitis atopic, Erythema, |
||||
DUPILUMAB, |
||||
| 186 | 25130607 |
US |
23 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 187 | 25130695 |
US |
44 | 2 |
Product use in unapproved indication, Dermatitis atopic, Anxiety, Injury, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 188 | 25130751 |
US |
33 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 189 | 25130844 |
US |
27 | 2 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 190 | 25131236 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 191 | 25131449 |
US |
75 | 1 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 192 | 25131938 |
US |
1 | |
Dermatitis atopic, Product administered at inappropriate site, |
||||
DUPILUMAB, |
||||
| 193 | 25131977 |
US |
18 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 194 | 25121191 |
US |
13 | 2 |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 195 | 25121212 |
US |
34 | 1 |
Dermatitis atopic, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 196 | 25121218 |
US |
36 | 2 |
Dermatitis atopic, Rash macular, |
||||
DUPILUMAB, |
||||
| 197 | 25121229 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 198 | 25121238 |
US |
9 | 2 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 199 | 25121244 |
US |
28 | 2 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 200 | 25121432 |
US |
62 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28